Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R. Morschhauser F, et al. Among authors: van eygen k. Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. Lancet Haematol. 2019. PMID: 31296423 Free article. Clinical Trial.
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F. Houot R, et al. Among authors: van hoof a, van eygen k, van den neste e. Leukemia. 2019 Mar;33(3):776-780. doi: 10.1038/s41375-018-0282-y. Epub 2018 Oct 5. Leukemia. 2019. PMID: 30291335 Free article. Clinical Trial. No abstract available.
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B. Thieblemont C, et al. Among authors: van eygen k. Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8. Br J Haematol. 2020. PMID: 31702836 Free PMC article. Clinical Trial.
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B. Thieblemont C, et al. Among authors: van hoof a, van eygen k. J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20. J Clin Oncol. 2017. PMID: 28426350 Clinical Trial.
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.
Bernard S, Ghesquieres H, Casasnovas RO, Griolet S, Gomes da Silva M, Feugier P, Morschhauser F, Trotman J, Renaud L, Greil R, García-Sancho AM, Grosicki S, van Eygen K, Copie-Bergman C, Haioun C, Thieblemont C. Bernard S, et al. Among authors: van eygen k. Blood Adv. 2021 Aug 10;5(15):2965-2968. doi: 10.1182/bloodadvances.2021004766. Blood Adv. 2021. PMID: 34338754 Free PMC article. No abstract available.
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 study investigators. Coiffier B, et al. Among authors: van eygen k. Br J Haematol. 2013 Nov;163(3):334-42. doi: 10.1111/bjh.12537. Epub 2013 Aug 23. Br J Haematol. 2013. PMID: 24032456 Free article. Clinical Trial.
Results from the Belgian mantle cell lymphoma registry.
Vergote V, Janssens A, André M, Bonnet C, Van Hende V, Van Den Neste E, Van Eygen K, Maerevoet M, Pranger D, Schroyens W, Debussche S, Maertens V, Beel K, Lemmens J, Caron C, Delrieu V, Van Den Broeck I, Vanstraelen G, Jacquy C, Schauvlieghe L, De Samblanx H, Madoe V, Meers S, Boulet D, Verhoef G, Van Hoof A. Vergote V, et al. Among authors: van hende v, van hoof a, van eygen k, van den neste e, van den broeck i. Acta Clin Belg. 2017 Jun;72(3):172-178. doi: 10.1080/17843286.2017.1293328. Epub 2017 Feb 22. Acta Clin Belg. 2017. PMID: 28222652 Free article.
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T, Havelange V, Theunissen K, Meers S, Benghiat FS, Gadisseur A, Vanstraelen G, Vellemans H, Bailly B, Granacher N, Lewalle P, De Becker A, Van Eygen K, Janssen M, Triffet A, Vrelust I, Deeren D, Mazure D, Bekaert J, Beck M, Selleslag D. Devos T, et al. Among authors: van eygen k. Ann Hematol. 2021 Jul;100(7):1723-1732. doi: 10.1007/s00277-021-04507-x. Epub 2021 May 4. Ann Hematol. 2021. PMID: 33942128 Free PMC article.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
52 results